Interpret the prothrombin time (PT) of 11.20 seconds and International Normalized Ratio (INR) of 1.08 and advise management for a patient on warfarin for deep‑vein thrombosis prevention/treatment or with a mechanical heart valve.

Subtherapeutic Anticoagulation Requiring Immediate Dose Adjustment

This patient has a subtherapeutic INR of 1.08 and requires an immediate increase in warfarin dose, with repeat INR testing in 3-7 days to ensure therapeutic range is achieved.

Clinical Interpretation

The laboratory results show:

• PT: 11.20 seconds (within normal range: 9.60-11.33)
• INR: 1.08 (essentially normal, reference 0.91-1.08)

This INR is critically below all therapeutic targets for warfarin therapy:

• DVT prevention/treatment target: 2.0-3.0 1
• Mechanical heart valve target: 2.5-3.5 (mitral position) or 2.0-3.0 (aortic bileaflet) 1

Management Algorithm

1. Immediate Warfarin Dose Adjustment

Increase the daily warfarin dose by 10-20% and recheck INR in 3-7 days 2. The patient is essentially unprotected from thromboembolism at this INR level.

• For DVT/PE patients: Risk of recurrent thrombosis increases sharply when INR falls below 2.0 3
• For mechanical valve patients: This represents dangerously inadequate anticoagulation with high thromboembolism risk 1, 4

2. Assess Need for Bridging Anticoagulation

Bridging with LMWH is NOT routinely recommended for a single subtherapeutic INR in stable patients 2. A 2008 retrospective study of 2,597 patients showed no significant difference in thromboembolic events between low-INR and therapeutic-INR cohorts when bridging was not used 2.

However, consider bridging therapy if:

• Mechanical mitral valve (highest thrombotic risk)
• History of prior thromboembolism
• Multiple consecutive subtherapeutic INRs
• Acute thrombotic symptoms present

3. Investigation of Subtherapeutic INR Causes

Identify why the INR dropped:

• Medication non-adherence (most common)
• New medications that induce warfarin metabolism (rifampin, carbamazepine, phenytoin) 1
• Dietary changes (increased vitamin K intake from green leafy vegetables)
• Decreased absorption (diarrhea, malabsorption)
• Hypothyroidism 1

4. Follow-up INR Timing

Recheck INR in 3-7 days after dose adjustment 2. The half-life of warfarin ranges from 21-89 hours depending on the enantiomer 1, so full effect of dose changes takes several days.

Once therapeutic INR is re-established with 2-3 consecutive measurements, return to routine monitoring intervals (up to 12 weeks for stable patients) 2.

Critical Pitfalls to Avoid

• Do not assume the patient is therapeutic based on the PT alone—the INR is the standardized measure that accounts for thromboplastin reagent variability 4
• Do not make small dose adjustments (5% changes)—these are often insufficient; 10-20% increases are appropriate for INRs this far below target
• Do not delay dose adjustment waiting for the next scheduled appointment—this patient needs intervention now
• Do not routinely bridge all subtherapeutic INRs—evidence shows this is unnecessary for most stable patients and increases bleeding risk 2

Target INR Ranges by Indication

For DVT/PE treatment or prevention:

• Target INR: 2.5 (range 2.0-3.0) 1

For mechanical heart valves:

• Bileaflet valve in aortic position: 2.5 (range 2.0-3.0) 1
• Tilting disk or bileaflet in mitral position: 3.0 (range 2.5-3.5) 1
• Caged ball/disk valves: 3.0 (range 2.5-3.5) plus aspirin 75-100 mg daily 1

The risk of thromboembolism increases substantially when INR falls below 2.0, while bleeding risk increases sharply above 4.0 3, 1.